Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT +0.78%100 EBIT per Share is $3.79 as of Jun. 2026. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.26 (Modestly Undervalued). Among 684 Medical Devices & Instruments companies, LeMaitre Vascular ranks better than 75.29% on this metric.
LeMaitre Vascular's EBIT per Share for the
three
months ended in Jun. 2026 was $0.96.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $3.79.
During the past 12 months, the average EBIT per Share Growth Rate of LeMaitre Vascular was 36.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 29.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 15.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 13.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for LeMaitre Vascular's EBIT per Share or its related term are showing as below:
LMAT'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -9.9 Med: 10.6 Max: 43.6
Current: 29.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of LeMaitre Vascular was 43.60% per year. The lowest was -9.90% per year. And the median was 10.60% per year.
LMAT's 3-Year EBIT Growth Rate is ranked better than 75.29% of 684
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs LMAT: 29.90
LeMaitre Vascular (NAS:LMAT) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
LeMaitre Vascular EBIT per Share Related Terms
LeMaitre Vascular EBIT per Share Historical Data
* Premium members only.
The historical data trend for LeMaitre Vascular's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.79
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular (LMAT) has a EBIT per Share of $3.79 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on LeMaitre Vascular and its competitors. According to the industry distribution chart, LeMaitre Vascular ranks #169 out of 684 companies in the Medical Devices & Instruments industry, placing it in the top 24.7%.
Is LeMaitre Vascular's EBIT per Share too high?
LeMaitre Vascular's current EBIT per Share is $3.79. The Medical Devices & Instruments industry median EBIT per Share is 9.60. LeMaitre Vascular's value of $3.79 is 60.5% below this industry median. Based on the distribution chart, LeMaitre Vascular ranks #169 out of 684 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's EBIT per Share compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #169 out of 684 companies for EBIT per Share. This places LeMaitre Vascular in the top 25% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.60. LeMaitre Vascular's value of $3.79 is 60.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current EBIT per Share of $3.79 is 60.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on LeMaitre Vascular and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current EBIT per Share is $3.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current EBIT per Share is $3.79 and 60.5% below the Medical Devices & Instruments industry median of 9.60. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current EBIT per Share is $3.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
EBIT per Share: $3.79
GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
Industry Position: 60.5% below the Medical Devices & Instruments median (#169 of 684)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score
Get the complete analysis for LMAT
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
